A BILL 
To amend the Controlled Substances Act with respect to 
fentanyl-related substances, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Save Americans from 
4
the Fentanyl Emergency Act of 2022’’ or the ‘‘SAFE Act 
5
of 2022’’. 
6
20:31 Mar 09, 2022
H6946
2 
•HR 6946 IH
SEC. 2. CLASS SCHEDULING OF FENTANYL-RELATED SUB-
1
STANCES. 
2
Section 202(c) of the Controlled Substances Act (21 
3
U.S.C. 812(c)) is amended by adding at the end of sched-
4
ule I the following: 
5
‘‘(e)(1) Unless specifically exempted or unless listed 
6
in another schedule, any material, compound, mixture, or 
7
preparation which contains any quantity of fentanyl-re-
8
lated substances, or which contains their salts, isomers, 
9
and salts of isomers whenever the existence of such salts, 
10
isomers, and salts of isomers is possible within the specific 
11
chemical designation. 
12
‘‘(2) In this subsection, except as provided in para-
13
graph (3), the term ‘fentanyl-related substance’ means 
14
any substance that is structurally related to fentanyl by 
15
one or more of the following modifications: 
16
‘‘(A) By replacement of the phenyl portion of 
17
the phenethyl group by any monocycle, whether or 
18
not further substituted in or on the monocycle. 
19
‘‘(B) By substitution in or on the phenethyl 
20
group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 
21
haloalkyl, amino, or nitro groups. 
22
‘‘(C) By substitution in or on the piperidine 
23
ring with alkyl, alkenyl, alkoxyl, ester, ether, 
24
hydroxyl, halo, haloalkyl, amino, or nitro groups. 
25
20:31 Mar 09, 2022
H6946
3 
•HR 6946 IH
‘‘(D) By replacement of the aniline ring with 
1
any aromatic monocycle whether or not further sub-
2
stituted in or on the aromatic monocycle. 
3
‘‘(E) By replacement of the N-propionyl group 
4
with another acyl group. 
5
‘‘(3) A substance that meets the criteria specified in 
6
paragraph (2) to be considered a fentanyl-related sub-
7
stance shall not be so considered as meeting such criteria 
8
if such substance— 
9
‘‘(A) is controlled by action of the Attorney 
10
General pursuant to section 201; 
11
‘‘(B) is expressly listed in this schedule or an-
12
other schedule by a statutory provision other than 
13
this subsection; or 
14
‘‘(C) is removed from this schedule, or resched-
15
uled to another schedule, pursuant to section 201(k). 
16
‘‘(4) The Attorney General shall publish in the Fed-
17
eral Register a list of individual substances that meet the 
18
definition of fentanyl-related substances in paragraph (2) 
19
within 60 days of determining such substances meet such 
20
definition. The absence of a substance on any such list 
21
does not negate the control status of such substance if 
22
the substance meets the criteria specified in paragraph (2) 
23
to be considered a fentanyl-related substance. 
24
20:31 Mar 09, 2022
H6946
4 
•HR 6946 IH
‘‘(5) Notwithstanding any other provision of this title 
1
or title III, fentanyl-related substances shall not be subject 
2
to quantity-based mandatory minimum penalties pursuant 
3
to subparagraph (A)(vi) or (B)(vi) of section 401(b)(1) of 
4
this title or paragraph (1)(F) or (2)(F) of section 1010(b) 
5
of title III.’’. 
6
SEC. 
3. 
PENALTY 
PROVISIONS 
WITH 
RESPECT 
TO 
7
FENTANYL-RELATED 
SUBSTANCES—DOMES-
8
TIC OFFENSES. 
9
Section 401(b)(1) of the Controlled Substances Act 
10
(21 U.S.C. 841(b)(1)) is amended— 
11
(1) in subparagraph (A), by striking clause (vi) 
12
and inserting the following: 
13
‘‘(vi)(I) 400 grams or more of a mixture or sub-
14
stance containing a detectable amount of fentanyl; 
15
or 
16
‘‘(II) 100 grams or more of a mixture or sub-
17
stance containing a detectable amount of any ana-
18
logue of fentanyl that is controlled in schedule I or 
19
II or that is treated as a schedule I controlled sub-
20
stance pursuant to section 203(a), except for a 
21
fentanyl-related substance as defined in schedule 
22
I(e) of section 202(c);’’; 
23
(2) in subparagraph (B), by striking clause (vi) 
24
and inserting the following: 
25
20:31 Mar 09, 2022
H6946
5 
•HR 6946 IH
‘‘(vi)(I) 40 grams or more of a mixture or sub-
1
stance containing a detectable amount of fentanyl; 
2
or 
3
‘‘(II) 10 grams or more of a mixture or sub-
4
stance containing a detectable amount of any ana-
5
logue of fentanyl that is controlled in schedule I or 
6
II or that is treated as a schedule I controlled sub-
7
stance pursuant to section 203(a), except for a 
8
fentanyl-related substance as defined in schedule 
9
I(e) of section 202(c);’’; and 
10
(3) in subparagraph (C), by inserting ‘‘, includ-
11
ing a fentanyl-related substance as defined in sched-
12
ule I(e) of section 202(c),’’ after ‘‘a controlled sub-
13
stance in schedule I or II,’’. 
14
SEC. 
4. 
PENALTY 
PROVISIONS 
WITH 
RESPECT 
TO 
15
FENTANYL-RELATED 
SUBSTANCES—IMPORT 
16
AND EXPORT OFFENSES. 
17
Section 1010(b) of the Controlled Substances Import 
18
and Export Act (21 U.S.C. 960(b)) is amended— 
19
(1) in paragraph (1), by striking subparagraph 
20
(F) and inserting the following: 
21
‘‘(F)(i) 400 grams or more of a mixture or sub-
22
stance containing a detectable amount of fentanyl; 
23
or 
24
20:31 Mar 09, 2022
H6946
6 
•HR 6946 IH
‘‘(ii) 100 grams or more of a mixture or sub-
1
stance containing a detectable amount of any ana-
2
logue of fentanyl that is controlled in schedule I or 
3
II or that is treated as a schedule I controlled sub-
4
stance pursuant to section 203(a) of the Controlled 
5
Substances Act, except for a fentanyl-related sub-
6
stance as defined in schedule I(e) of section 202(c) 
7
of the Controlled Substances Act;’’; 
8
(2) in paragraph (2), by striking subparagraph 
9
(F) and inserting the following: 
10
‘‘(F)(i) 40 grams or more of a mixture or sub-
11
stance containing a detectable amount of fentanyl; 
12
or 
13
‘‘(ii) 10 grams or more of a mixture or sub-
14
stance containing a detectable amount of any ana-
15
logue of fentanyl that is controlled in schedule I or 
16
II or that is treated as a schedule I controlled sub-
17
stance pursuant to section 203(a) of the Controlled 
18
Substances Act, except for a fentanyl-related sub-
19
stance as defined in schedule I(e) of section 202(c) 
20
of the Controlled Substances Act;’’; and 
21
(3) in paragraph (3), by inserting ‘‘including a 
22
fentanyl-related substance as defined in schedule 
23
I(e) of section 202(c) of the Controlled Substances 
24
20:31 Mar 09, 2022
H6946
7 
•HR 6946 IH
Act,’’ after ‘‘a controlled substance in schedule I or 
1
II,’’. 
2
SEC. 5. REMOVAL FROM SCHEDULE I OF FENTANYL-RE-
3
LATED SUBSTANCES. 
4
Section 201 of the Controlled Substances Act (21 
5
U.S.C. 811) is amended by adding at the end the following 
6
new subsection: 
7
‘‘(k) REMOVAL FROM SCHEDULE I OF FENTANYL- 
8
RELATED SUBSTANCES.— 
9
‘‘(1) DETERMINATION
RESULTING
IN
RE-
10
MOVAL.—If the Secretary determines, taking into 
11
consideration factors as set forth in paragraph (3), 
12
that a fentanyl-related substance has a potential for 
13
abuse that is less than the drugs or other substances 
14
in schedule V— 
15
‘‘(A) the Secretary shall submit to the At-
16
torney General a scientific and medical evalua-
17
tion of that fentanyl-related substance sup-
18
porting that determination; 
19
‘‘(B) the Secretary shall submit any such 
20
evaluation and determination in writing and in-
21
clude the bases therefor; 
22
‘‘(C) the scientific and medical determina-
23
tion of the Secretary contained in such evalua-
24
20:31 Mar 09, 2022
H6946
8 
•HR 6946 IH
tion shall be binding on the Attorney General; 
1
and 
2
‘‘(D) not later than 90 days after receiving 
3
such evaluation and determination, the Attor-
4
ney General shall issue an order removing such 
5
fentanyl-related substance from the schedules 
6
under section 202. 
7
‘‘(2) DETERMINATION RESULTING IN RESCHED-
8
ULING.—If the Secretary determines, taking into 
9
consideration factors as set forth in paragraph (3), 
10
that a fentanyl-related substance has a potential for 
11
abuse that is less than the drugs or other substances 
12
in schedules I and II— 
13
‘‘(A) the Secretary shall submit to the At-
14
torney General a scientific and medical evalua-
15
tion of that fentanyl-related substance sup-
16
porting that determination; 
17
‘‘(B) the Secretary shall submit any such 
18
evaluation and determination in writing and in-
19
clude the bases therefor; 
20
‘‘(C) the scientific and medical determina-
21
tion of the Secretary contained in such evalua-
22
tion shall be binding on the Attorney General; 
23
and 
24
20:31 Mar 09, 2022
H6946
9 
•HR 6946 IH
‘‘(D) not later than 90 days after receiving 
1
such evaluation, the Attorney General shall 
2
issue an order removing such fentanyl-related 
3
substance from schedule I and controlling such 
4
substance under schedule III. 
5
‘‘(3) EVALUATION FACTORS.— 
6
‘‘(A) IN
GENERAL.—In making a deter-
7
mination under paragraph (1) or (2), the Sec-
8
retary— 
9
‘‘(i) shall consider— 
10
‘‘(I) the factor listed in para-
11
graph (2) of subsection (c); 
12
‘‘(II) the factors listed in para-
13
graphs (1), (3), and (6) of such sub-
14
section to the extent evidence exists 
15
with respect to such factors; and 
16
‘‘(III) any information submitted 
17
to the Secretary by the Attorney Gen-
18
eral for purposes of such determina-
19
tion; and 
20
‘‘(ii) may consider the factors listed in 
21
paragraphs (4), (5), and (7) of subsection 
22
(c) if the Secretary finds that evidence ex-
23
ists with respect to such factors. 
24
20:31 Mar 09, 2022
H6946
10 
•HR 6946 IH
‘‘(B) CONSIDERATION OF SCIENTIFIC EVI-
1
DENCE OF PHARMACOLOGICAL EFFECT.— 
2
‘‘(i) IN GENERAL.—For the purposes 
3
of subparagraph (A)(i)(I), consideration by 
4
the Secretary of the results of an assess-
5
ment consisting of the studies described in 
6
clause (ii) shall suffice to constitute consid-
7
eration of the factor listed in paragraph 
8
(2) of subsection (c) if— 
9
‘‘(I) each such study is per-
10
formed according to scientific methods 
11
and protocols commonly accepted in 
12
the scientific community; and 
13
‘‘(II) the Secretary determines 
14
that such assessment is adequate for 
15
such purposes. 
16
‘‘(ii) 
DESCRIBED
STUDIES.—The 
17
studies described in this clause are any of 
18
the following: 
19
‘‘(I) A receptor binding study 
20
that can demonstrate whether the 
21
substance has affinity for the human 
22
mu opioid receptor. 
23
‘‘(II) An in vitro functional assay 
24
that can demonstrate whether the 
25
20:31 Mar 09, 2022
H6946
11 
•HR 6946 IH
substance has agonist activity at the 
1
human mu opioid receptor. 
2
‘‘(III) One or more in vivo ani-
3
mal behavioral studies that can dem-
4
onstrate whether the substance has 
5
abuse-related drug effects consistent 
6
with mu opioid agonist activity, such 
7
as demonstrating similarity to the ef-
8
fects of morphine. 
9
‘‘(4) ADVANCE
NOTICE
REGARDING
EVALUA-
10
TION AND CONCLUSION.—The Secretary shall give 
11
the Attorney General at least 30 days notice before 
12
sending the Attorney General an evaluation and de-
13
termination under paragraph (1) or (2) with respect 
14
to a fentanyl-related substance. 
15
‘‘(5) EXCEPTION FOR TREATY OBLIGATIONS.— 
16
If a fentanyl-related substance is a substance that 
17
the United States is obligated to control under inter-
18
national treaties, conventions, or protocols in effect 
19
on the date of enactment of the Save Americans 
20
from the Fentanyl Emergency Act of 2022, this sub-
21
section shall not require the Attorney General— 
22
‘‘(A) to remove such substance from con-
23
trol; or 
24
20:31 Mar 09, 2022
H6946
12 
•HR 6946 IH
‘‘(B) to place such substance in a schedule 
1
less restrictive than that which the Attorney 
2
General determines is necessary to carry out 
3
such obligations. 
4
‘‘(6) IDENTIFICATION OF FENTANYL-RELATED 
5
SUBSTANCES.—If the Attorney General or any offi-
6
cial of the Department of Justice determines that a 
7
substance is a fentanyl-related substance, the Attor-
8
ney General shall— 
9
‘‘(A) within 30 days of such determination, 
10
notify the Secretary; and 
11
‘‘(B) include in such notification the iden-
12
tity of the substance, its structure, and the 
13
basis for the determination. 
14
‘‘(7) PETITIONS FOR REMOVING A FENTANYL- 
15
RELATED SUBSTANCE.— 
16
‘‘(A) IN GENERAL.—If a person petitions 
17
the Attorney General to remove a fentanyl-re-
18
lated substance from schedule I(e) or to re-
19
schedule such a substance to another schedule, 
20
the Attorney General shall consider such a peti-
21
tion in accordance with the procedures and 
22
standards set forth in— 
23
‘‘(i) subsections (a) and (b) of this 
24
section; and 
25
20:31 Mar 09, 2022
H6946
13 
•HR 6946 IH
‘‘(ii) section 1308.43 of title 21, Code 
1
of Federal Regulations (or any successor 
2
regulations). 
3
‘‘(B) ATTORNEY
GENERAL
TO
INFORM 
4
SECRETARY.—Within 30 days of receiving such 
5
a petition, the Attorney General shall forward a 
6
copy of the petition to the Secretary. 
7
‘‘(C) DETERMINATION
PROCEDURE
NOT 
8
PRECLUDED BY FILING OF PETITION.—The fil-
9
ing of a petition under this paragraph shall not 
10
preclude the Secretary from making a deter-
11
mination and sending an evaluation under para-
12
graph (1) or (2). 
13
‘‘(8) RULE
OF
CONSTRUCTION.—Nothing in 
14
this subsection shall be construed to preclude the At-
15
torney General from transferring a substance listed 
16
in schedule I to another schedule, or removing such 
17
substance entirely from the schedules, pursuant to 
18
other provisions of this section and section 202. 
19
‘‘(9) SUBSEQUENT CONTROLLING OF REMOVED 
20
SUBSTANCE.—A substance removed from schedule I 
21
pursuant to this subsection may, at any time, be 
22
controlled pursuant to the other provisions of this 
23
section and section 202 without regard to the re-
24
moval pursuant to this subsection. 
25
20:31 Mar 09, 2022
H6946
14 
•HR 6946 IH
‘‘(10) EVALUATIONS
OR
STUDIES.—The Sec-
1
retary may enter into contracts or other agreements 
2
to conduct or support evaluations or studies of 
3
fentanyl-related substances. 
4
‘‘(11) DEFINITION.—In this subsection, the 
5
term ‘fentanyl-related substance’ means a fentanyl- 
6
related substance as defined in schedule I(e) of sec-
7
tion 202(c).’’. 
8
SEC. 6. PAST CASES INVOLVING REMOVED OR RESCHED-
9
ULED SUBSTANCES. 
10
(a) DOMESTIC CASES.—Section 401(b) of the Con-
11
trolled Substances Act (21 U.S.C. 841(b)) is amended by 
12
adding at the end the following: 
13
‘‘(8) PAST CONVICTIONS INVOLVING FENTANYL-RE-
14
LATED SUBSTANCE.— 
15
‘‘(A) IN GENERAL.—In the case of a defendant 
16
whose offense of conviction under this title involved 
17
a fentanyl-related substance (as defined in schedule 
18
I(e) of section 202(c) as of the date the offense was 
19
committed) that has since been removed from des-
20
ignation as a fentanyl-related substance for purposes 
21
of this title and has been placed on any schedule 
22
other than schedule I or II or has been removed 
23
from the controlled substance schedules, the sen-
24
tencing court may, on motion of the defendant, the 
25
20:31 Mar 09, 2022
H6946
15 
•HR 6946 IH
Bureau of Prisons, the attorney for the Government, 
1
or on its own motion, after considering the factors 
2
set forth in section 3553(a) of title 18, United 
3
States Code, vacate the previously imposed sentence, 
4
or impose a reduced sentence on any count of con-
5
viction as if the removal or placement was in effect 
6
at the time that the offense was committed. Nothing 
7
in this section may be construed to require a court 
8
to vacate or reduce any sentence. 
9
‘‘(B) DEFENDANT
NOT
REQUIRED
TO
BE 
10
PRESENT.—Notwithstanding rule 43 of the Federal 
11
Rules of Criminal Procedure, the defendant is not 
12
required to be present at any hearing on whether to 
13
vacate or reduce a sentence pursuant to this sec-
14
tion.’’. 
15
(b) IMPORT AND EXPORT CASES.—Section 1010(b) 
16
of the Controlled Substances Import and Export Act (21 
17
U.S.C. 960(b)) is amended by adding at the end the fol-
18
lowing: 
19
‘‘(8) In the case of a defendant whose offense of con-
20
viction under this title involved a fentanyl-related sub-
21
stance (as defined in schedule I(e) of section 202(c) of 
22
the Controlled Substances Act as of the date the offense 
23
was committed) that has since been removed from des-
24
ignation as a fentanyl-related substance for purposes of 
25
20:31 Mar 09, 2022
H6946
16 
•HR 6946 IH
this title and has been placed on any schedule other than 
1
schedule I or II or has been removed from the controlled 
2
substance schedules, the sentencing court may, on motion 
3
of the defendant, the Bureau of Prisons, the attorney for 
4
the Government, or on its own motion, after considering 
5
the factors set forth in section 3553(a) of title 18, United 
6
States Code, vacate the previously imposed sentence, or 
7
impose a reduced sentence on any count of conviction as 
8
if the removal or placement was in effect at the time that 
9
the offense was committed. Nothing in this section may 
10
be construed to require a court to vacate or reduce any 
11
sentence.’’. 
12
SEC. 7. REGISTRATION REQUIREMENTS RELATED TO RE-
13
SEARCH. 
14
(a) ALTERNATIVE
REGISTRATION
PROCESS
FOR 
15
SCHEDULE I RESEARCH.—Section 303 of the Controlled 
16
Substances Act (21 U.S.C. 823) is amended by adding at 
17
the end the following new subsection: 
18
‘‘(l) SPECIAL PROVISIONS FOR THOSE CONDUCTING 
19
CERTAIN RESEARCH WITH SCHEDULE I CONTROLLED 
20
SUBSTANCES.— 
21
‘‘(1) IN GENERAL.—Notwithstanding subsection 
22
(f), a practitioner may conduct research that is de-
23
scribed in paragraph (2) and that is with one or 
24
20:31 Mar 09, 2022
H6946
17 
•HR 6946 IH
more controlled substances in schedule I if one of 
1
the following conditions is satisfied: 
2
‘‘(A) RESEARCHER
WITH
A
CURRENT 
3
SCHEDULE I OR II RESEARCH REGISTRATION.— 
4
If the practitioner is registered to conduct re-
5
search with a controlled substance in schedule 
6
I or II, the practitioner may conduct research 
7
under this paragraph 30 days after the practi-
8
tioner has sent a notice to the Attorney General 
9
containing the following information, with re-
10
spect to each substance with which the research 
11
will be conducted: 
12
‘‘(i) The chemical name of the sub-
13
stance. 
14
‘‘(ii) The quantity of the substance to 
15
be used in such research. 
16
‘‘(iii) Demonstration that the research 
17
is described in paragraph (2), which dem-
18
onstration can be satisfied— 
19
‘‘(I) in the case of research de-
20
scribed in paragraph (2)(A), by sup-
21
plying the number of the application 
22
submitted under section 505(i) of the 
23
Federal Food, Drug, and Cosmetic 
24
Act or section 351(a)(3) of the Public 
25
20:31 Mar 09, 2022
H6946
18 
•HR 6946 IH
Health Service Act and the sponsor of 
1
record on such application; or 
2
‘‘(II) in the case of research de-
3
scribed in paragraph (2)(B), by iden-
4
tifying the sponsoring agency and 
5
supplying the number of the grant, 
6
contract, cooperative agreement, other 
7
transaction, or project. 
8
‘‘(iv) Demonstration that the re-
9
searcher is authorized to conduct research 
10
with respect to the substance under the 
11
laws of the State in which the research will 
12
take place. 
13
‘‘(B) RESEARCHER WITHOUT A CURRENT 
14
SCHEDULE I OR II RESEARCH REGISTRATION.— 
15
If the practitioner is not currently registered to 
16
conduct research with a controlled substance in 
17
schedule I or II— 
18
‘‘(i) the practitioner may send a no-
19
tice to the Attorney General containing the 
20
information listed in subparagraph (A), 
21
with respect to each substance with which 
22
the research will be conducted; 
23
20:31 Mar 09, 2022
H6946
19 
•HR 6946 IH
‘‘(ii) the Attorney General shall treat 
1
such notice as a sufficient application for 
2
a research registration; and 
3
‘‘(iii) within 45 days after receiving 
4
such a notice that contains all information 
5
required by subparagraph (A), the Attor-
6
ney General shall register the applicant, or 
7
serve an order to show cause upon the ap-
8
plicant in accordance with section 304(c). 
9
‘‘(C) VERIFICATION
OF
INFORMATION.— 
10
On request from the Attorney General, the Sec-
11
retary of Health and Human Services or the 
12
Secretary of Veterans Affairs, as appropriate, 
13
shall verify information submitted by an appli-
14
cant under subparagraph (A)(iii). 
15
‘‘(2) RESEARCH SUBJECT TO EXPEDITED PRO-
16
CEDURE.—Research described in this paragraph is 
17
research that— 
18
‘‘(A) is the subject of an application under 
19
section 505(i) of the Federal Food, Drug, and 
20
Cosmetic Act or section 351(a)(3) of the Public 
21
Health Service Act for the investigation of a 
22
drug which is in effect in accordance with sec-
23
tion 312.40 of title 21, Code of Federal Regula-
24
tions; or 
25
20:31 Mar 09, 2022
H6946
20 
•HR 6946 IH
‘‘(B) is conducted by the Department of 
1
Health and Human Services, the Department of 
2
Justice, or the Department of Veterans Affairs 
3
or is funded partly or entirely by a grant, con-
4
tract, cooperative agreement, or other trans-
5
action from the Department of Health and 
6
Human Services, the Department of Justice, or 
7
the Department of Veterans Affairs. 
8
‘‘(3) ELECTRONIC SUBMISSIONS.—The Attorney 
9
General shall provide a means to allow practitioners 
10
to submit notifications under paragraph (1) elec-
11
tronically. 
12
‘‘(4) LIMITATION ON AMOUNTS.—A practitioner 
13
conducting research with a controlled substance in 
14
schedule I pursuant to this subsection shall be al-
15
lowed to possess only the amounts of the controlled 
16
substance in schedule I identified in— 
17
‘‘(A) the notification to the Attorney Gen-
18
eral under paragraph (1); or 
19
‘‘(B) if the practitioner needs additional 
20
amounts for the research, a supplemental notifi-
21
cation under this subsection that includes the 
22
practitioner’s name, the additional quantity 
23
needed of the substance, and an attestation 
24
that the research to be conducted with the sub-
25
20:31 Mar 09, 2022
H6946
21 
•HR 6946 IH
stance is consistent with the scope of the re-
1
search that was the subject of the notification 
2
under paragraph (1). 
3
‘‘(5) IMPORTATION
AND
EXPORTATION
RE-
4
QUIREMENTS NOT AFFECTED.—Nothing in this sec-
5
tion alters the requirements of part A of title III re-
6
garding the importation and exportation of con-
7
trolled substances.’’. 
8
(b) SEPARATE REGISTRATIONS NOT REQUIRED FOR 
9
ADDITIONAL RESEARCHER IN SAME INSTITUTION.—Sub-
10
section (c) of section 302 of the Controlled Substances Act 
11
(21 U.S.C. 822) is amended by adding at the end the fol-
12
lowing: 
13
‘‘(4) An agent or employee of a research insti-
14
tution that is conducting research with a controlled 
15
substance if— 
16
‘‘(A) such agent or employee is acting 
17
within the scope of his or her professional prac-
18
tice; 
19
‘‘(B) another agent or employee of such in-
20
stitution is registered to conduct research with 
21
a controlled substance in the same schedule; 
22
‘‘(C) the researcher who is so registered— 
23
‘‘(i) informs the Attorney General of 
24
the name, position title, and employing in-
25
20:31 Mar 09, 2022
H6946
22 
•HR 6946 IH
stitution of the agent or employee who is 
1
not separately registered; 
2
‘‘(ii) authorizes such agent or em-
3
ployee to perform research under the reg-
4
istered researcher’s registration; and 
5
‘‘(iii) affirms that all acts taken by 
6
such agent or employee involving controlled 
7
substances shall be attributable to the reg-
8
istered researcher, as if the researcher had 
9
directly committed such acts, for purposes 
10
of any proceeding under section 304(a) to 
11
suspend or revoke the registration of the 
12
registered researcher; and 
13
‘‘(D) the Attorney General does not, within 
14
30 days of receiving the information, authoriza-
15
tion, and affirmation described in subparagraph 
16
(C), refuse, for a reason listed in section 
17
304(a), to allow such agent or employee to pos-
18
sess such substance without a separate registra-
19
tion.’’. 
20
(c) SINGLE REGISTRATION FOR RELATED RESEARCH 
21
SITES.—Such section 302(e) of the Controlled Substances 
22
Act (21 U.S.C. 822(e)) is amended by adding at the end 
23
the following: 
24
20:31 Mar 09, 2022
H6946
23 
•HR 6946 IH
‘‘(3)(A) Notwithstanding paragraph (1), a person 
1
registered to conduct research with a controlled substance 
2
under section 303(f) may conduct such research at mul-
3
tiple sites under a single registration if— 
4
‘‘(i) such research occurs exclusively at sites 
5
which are all within the same city or county and are 
6
all under the control of the same institution, organi-
7
zation, or agency; and 
8
‘‘(ii) the researcher notifies the Attorney Gen-
9
eral, prior to commencing such research, of all sites 
10
where— 
11
‘‘(I) the research will be conducted; or 
12
‘‘(II) the controlled substance will be 
13
stored or administered. 
14
‘‘(B) A site described by subparagraph (A) shall be 
15
included in such registration only if the researcher has no-
16
tified the Attorney General of such site— 
17
‘‘(i) in the application for such registration; or 
18
‘‘(ii) before the research is conducted, or before 
19
the controlled substance is stored or administered, at 
20
such site. 
21
‘‘(C) The Attorney General may, in consultation with 
22
the Secretary of Health and Human Services, issue regu-
23
lations addressing— 
24
20:31 Mar 09, 2022
H6946
24 
•HR 6946 IH
‘‘(i) the manner in which controlled substances 
1
may be delivered to research sites described in sub-
2
paragraph (A); 
3
‘‘(ii) the storage and security of controlled sub-
4
stances at such research sites; 
5
‘‘(iii) the maintenance of records for such re-
6
search sites; and 
7
‘‘(iv) any other matters necessary to ensure ef-
8
fective controls against diversion at such research 
9
sites.’’. 
10
(d) NEW INSPECTION NOT REQUIRED IN CERTAIN 
11
SITUATIONS.—Subsection (f) of section 302 of the Con-
12
trolled Substances Act (21 U.S.C. 822) is amended— 
13
(1) by striking ‘‘(f) The’’ and inserting ‘‘(f)(1) 
14
The’’; and 
15
(2) by adding at the end the following: 
16
‘‘(2)(A) A new inspection by the Attorney General of 
17
a registered location is not required if a person is reg-
18
istered under this title to conduct research with a con-
19
trolled substance and applies for a registration, or for a 
20
modification of a registration, to conduct research with a 
21
second controlled substance that is— 
22
‘‘(i) in the same schedule as the first controlled 
23
substance; or 
24
20:31 Mar 09, 2022
H6946
25 
•HR 6946 IH
‘‘(ii) is in a schedule with a higher numerical 
1
designation than the schedule of the first controlled 
2
substance. 
3
‘‘(B) Nothing in this paragraph shall prohibit the At-
4
torney General from conducting any inspection if the At-
5
torney General deems it necessary to ensure that the reg-
6
istrant maintains effective controls against diversion.’’. 
7
(e) CONTINUATION OF RESEARCH ON SUBSTANCES 
8
NEWLY ADDED TO SCHEDULE I.—Section 302 of the 
9
Controlled Substances Act (21 U.S.C. 822) is amended 
10
by adding at the end the following: 
11
‘‘(h) CONTINUATION OF RESEARCH ON SUBSTANCES 
12
NEWLY ADDED TO SCHEDULE I.—If a person is con-
13
ducting research on a substance at the time the substance 
14
is added to schedule I, and such person is already reg-
15
istered under this title to conduct research with a con-
16
trolled substance in schedule I, then— 
17
‘‘(1) the person shall, within 90 days of the 
18
scheduling in schedule I, submit a completed appli-
19
cation for registration under this title or modifica-
20
tion of an existing registration under this title, to 
21
conduct research on such substance, in accordance 
22
with regulations issued by the Attorney General; 
23
20:31 Mar 09, 2022
H6946
26 
•HR 6946 IH
‘‘(2) the person may, notwithstanding sub-
1
sections (a) and (b), continue to conduct the re-
2
search on such substance until— 
3
‘‘(A) the person withdraws such applica-
4
tion; or 
5
‘‘(B) the Attorney General serves on the 
6
person an order to show cause proposing the 
7
denial of the application pursuant to section 
8
304(c); 
9
‘‘(3) if the Attorney General serves such an 
10
order to show cause and the person requests a hear-
11
ing, such hearing shall be held on an expedited basis 
12
and not later than 45 days after the request is 
13
made, except that the hearing may be held at a later 
14
time if so requested by the person; and 
15
‘‘(4) if the person sends a copy of the applica-
16
tion required by paragraph (1) to a manufacturer or 
17
distributor of such substance, receipt of such copy 
18
by such manufacturer or distributor shall constitute 
19
sufficient evidence that the person is authorized to 
20
receive such substance.’’. 
21
(f) TREATMENT OF CERTAIN MANUFACTURING AC-
22
TIVITIES AS COINCIDENT TO RESEARCH.—Section 302 of 
23
the Controlled Substances Act (21 U.S.C. 822), as amend-
24
20:31 Mar 09, 2022
H6946
27 
•HR 6946 IH
ed by subsection (e), is further amended by adding at the 
1
end the following: 
2
‘‘(i) TREATMENT OF CERTAIN MANUFACTURING AC-
3
TIVITIES AS COINCIDENT TO RESEARCH.— 
4
‘‘(1) IN
GENERAL.—Except as specified in 
5
paragraph (3), a person who is registered to perform 
6
research on a controlled substance may perform 
7
manufacturing activities with small quantities of 
8
that substance, including activities listed in para-
9
graph (2), without being required to obtain a manu-
10
facturing registration, if such activities are per-
11
formed for the purpose of the research and if the ac-
12
tivities and the quantities of the substance involved 
13
in those activities are stated in— 
14
‘‘(A) a notification submitted to the Attor-
15
ney General under section 303(l); 
16
‘‘(B) a protocol filed with an application 
17
for registration approval under section 303(f); 
18
or 
19
‘‘(C) a notification to the Attorney General 
20
that includes the registrant’s name and an at-
21
testation that the research to be conducted with 
22
the small quantities of manufactured substance 
23
is consistent with the scope of the research that 
24
is the basis for the registration. 
25
20:31 Mar 09, 2022
H6946
28 
•HR 6946 IH
‘‘(2) ACTIVITIES
INCLUDED.—Activities per-
1
mitted under paragraph (1) include— 
2
‘‘(A) processing the substance to create ex-
3
tracts, tinctures, oils, solutions, derivatives, or 
4
other forms of the substance consistent with the 
5
information provided as part of a notification 
6
submitted to the Attorney General under sec-
7
tion 303(l) or a research protocol filed with the 
8
application for registration approval; and 
9
‘‘(B) dosage form development studies per-
10
formed for the purpose of satisfying regulatory 
11
requirements of the Food and Drug Adminis-
12
tration for submitting an investigational new 
13
drug application. 
14
‘‘(3) EXCEPTION
REGARDING
MARIHUANA.— 
15
The authority under paragraph (1) to manufacture 
16
substances does not include authority to grow mari-
17
huana.’’. 
18
(g) TRANSPARENCY REGARDING SPECIAL PROCE-
19
DURES.—Section 303 of such Act (21 U.S.C. 823), as 
20
amended by subsection (a), is further amended by adding 
21
at the end the following: 
22
‘‘(m) TRANSPARENCY REGARDING SPECIAL PROCE-
23
DURES.— 
24
20:31 Mar 09, 2022
H6946
29 
•HR 6946 IH
‘‘(1) IN GENERAL.—If the Attorney General de-
1
termines, with respect to a controlled substance, that 
2
an application by a practitioner to conduct research 
3
with such substance should be considered under a 
4
process, or subject to criteria, different from the 
5
process or criteria applicable to applications to con-
6
duct research with other controlled substances in the 
7
same schedule, the Attorney General shall make 
8
public, including by posting on the website of the 
9
Drug Enforcement Administration— 
10
‘‘(A) the identities of all substances for 
11
which such determinations have been made; 
12
‘‘(B) the process and criteria that will be 
13
applied to applications to conduct research with 
14
such substances; and 
15
‘‘(C) how such process and criteria differ 
16
from those applicable to applications to conduct 
17
research with other controlled substances in the 
18
same schedule. 
19
‘‘(2) TIMING OF POSTING.—The Attorney Gen-
20
eral shall make such information public upon mak-
21
ing such determination, regardless of whether a 
22
practitioner has submitted such an application at 
23
that time.’’. 
24
20:31 Mar 09, 2022
H6946
30 
•HR 6946 IH
SEC. 8. RULEMAKING. 
1
(a) INTERIM FINAL RULES.—The Attorney Gen-
2
eral— 
3
(1) not later than 1 year of the date of enact-
4
ment of this Act, shall issue rules to implement this 
5
Act and the amendments made by this Act; and 
6
(2) may issue such rules as interim final rules. 
7
(b) PROCEDURE FOR FINAL RULE.—A rule issued by 
8
the Attorney General as an interim final rule under sub-
9
section (a) shall become immediately effective as an in-
10
terim final rule without requiring the Attorney General to 
11
demonstrate good cause therefor. The interim final rule 
12
shall give interested persons the opportunity to comment 
13
and to request a hearing. After the conclusion of such pro-
14
ceedings, the Attorney General shall issue a final rule in 
15
accordance with section 553 of title 5, United States Code. 
16
SEC. 9. GAO REPORT. 
17
(a) IN GENERAL.—Not more than 4 years after the 
18
date of enactment of this Act, the Comptroller General 
19
of the United States shall submit to the Committees on 
20
Energy and Commerce and the Judiciary of the House 
21
of Representatives and the Committee on the Judiciary 
22
of the Senate a report analyzing the implementation and 
23
impact, to the extent information is available, of perma-
24
nent class scheduling pursuant to schedule I(e) of section 
25
202(c) of the Controlled Substances Act, as added by sec-
26
20:31 Mar 09, 2022
H6946
31 
•HR 6946 IH
tion 2 of this Act, of fentanyl-related substances (as de-
1
fined in such schedule I(e)), which report shall include— 
2
(1) an analysis of the impact on research of 
3
fentanyl-related substances; 
4
(2) an analysis of any actions taken to remove 
5
or reschedule in a different class any fentanyl-re-
6
lated substance; 
7
(3) an analysis of the impact of permanent 
8
scheduling on the unlawful importation, manufac-
9
ture, trafficking, and use of fentanyl-related sub-
10
stances, taking into consideration data collected con-
11
cerning the proliferation of fentanyl-related sub-
12
stances since class scheduling was instituted; 
13
(4) an analysis of sentences attributable to 
14
criminal charges involving fentanyl-related sub-
15
stances, comparing those sentences to sentences at-
16
tributable to criminal charges involving fentanyl and 
17
individually scheduled fentanyl analogues; and 
18
(5) an analysis of the efficacy of class sched-
19
uling generally, in terms of reducing the prolifera-
20
tion of new controlled substance analogues. 
21
(b) CONSULTATIONS.—In developing the report re-
22
quired by subsection (a), the Comptroller General— 
23
(1) shall consider the views of the Secretary of 
24
Health and Human Services, the Attorney General, 
25
20:31 Mar 09, 2022
H6946
32 
•HR 6946 IH
the Secretary of Homeland Security, the Secretary 
1
of State, the Director of the Office of National Drug 
2
Control Policy, the scientific and medical research 
3
community, the State and local law enforcement 
4
community, and the civil rights and criminal justice 
5
reform communities; and 
6
(2) to the greatest extent possible, should base 
7
such report on reliable data and empirical informa-
8
tion. 
9
Æ 
20:31 Mar 09, 2022
H6946
